Biohaven .(US:BHVN) Prnewswireยท2025-09-12 12:45Core Viewpoint - A class action securities lawsuit has been filed against Biohaven Ltd. alleging securities fraud that affected investors between March 24, 2023, and May 14, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that Biohaven Ltd. made false statements regarding the regulatory prospects of its product candidate, troriluzole, and overstated the efficacy of BHV-7000 for treating bipolar disorder [2]. - It is alleged that the misleading statements would likely have a significant negative impact on Biohaven's business and financial condition once revealed [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until September 12, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].